Drug profile · INN
empagliflozin
JARDIANCE
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
empagliflozin (JARDIANCE) is an FDA-listed pharmaceutical active ingredient. Associated with Boehringer Ingelheim Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
INN empagliflozin
Brand JARDIANCE
Route ORAL
Formulation TABLET, EXTENDED RELEASE
ATC code A10BD19
Originator Boehringer Ingelheim Pty Ltd
Frequently asked questions
What is empagliflozin?
empagliflozin (JARDIANCE) is an FDA-listed pharmaceutical active ingredient. Associated with Boehringer Ingelheim Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for empagliflozin?
JARDIANCE is a marketed brand name for empagliflozin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of empagliflozin?
empagliflozin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.